SALSALATE

US Previously Marketed

First approved in 1995

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H10O5
Molecular Weight	258.2262
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O

InChI

InChIKey=WVYADZUPLLSGPU-UHFFFAOYSA-N

InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C14H10O5
Molecular Weight	258.2262
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23 Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 316 Sources: http://www.rxlist.com/disalcid-drug/indications-dosage.htm	Palliative	Approved 8429	DISALCID Approved Use Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder.
Osteoarthritis 157 Sources: http://www.rxlist.com/disalcid-drug/indications-dosage.htm	Palliative	Approved 8429	DISALCID Approved Use Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
Type 2 diabetes mellitus 259 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23817699	Primary	Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Modulation of endothelial cell activation in sickle cell disease: a pilot study.	2001 Apr 1	11264155
Lichenoid drug eruption to salsalate.	2001 Oct	11568758
Blood pressure elevation in a patient treated with salsalate.	2002 Apr	11918510
Nonsteroidal antiinflammatory drug starter packs for chronic musculoskeletal pain.	2002 Jul	12126217
Variable effects of nonsteroidal antiinflammatory agents on thyroid test results.	2003 Dec	14671157
Interaction of rofecoxib and celecoxib with warfarin.	2003 Jul 1	12901032
Aspirin and NSAID sensitivity.	2004 Aug	15242723
Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2.	2005 Jan 15	15698578
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells.	2005 Jan-Feb	15796154
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.	2006	16808554
Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.	2006 Sep	16880431
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.	2008 Aug	18443205
Salsalate improves glycemia and inflammatory parameters in obese young adults.	2008 Feb	17959861
Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes.	2008 Jul	18594064
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.	2008 Mar 12	18317009
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.	2008 May	19337387
Role of NFkappaB in age-related vascular endothelial dysfunction in humans.	2009 Aug 10	20157550
Inflammation, insulin resistance, and type 2 diabetes: back to the future?	2009 Feb	19171748
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.	2009 Jan	18835953
Serum concentration-dependent hepatotoxicity in individuals receiving oral salsalate.	2009 Jun	18770032
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.	2009 Mar	19104769
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.	2009 Mar 10	19237660
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury.	2009 Oct	19585463
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation.	2009 Sep	19581423
Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice.	2010	21403905
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats.	2010 Dec	20876710
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.	2010 Jul	20587709
Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.	2010 Jul 31	20613460
Potential role of salicylates in type 2 diabetes.	2010 Jul-Aug	20516365
Delayed recrudescence to toxic salicylate concentrations after salsalate overdose.	2010 Jun	20405267
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.	2010 Mar 16	20231565
Summaries for patients. The effects of salsalate on blood sugar control in people with type 2 diabetes.	2010 Mar 16	20231550
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects.	2010 Nov	22043213
An overview of salsalate as a potential antidiabetic therapy.	2010 Nov	21225023
A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease.	2010 Nov	20713682
Wet oxidation of salicylic acid solutions.	2010 Nov 15	20979409
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.	2010 Sep	20080359

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:10:16 UTC 2023` Edited by `admin` on `Fri Dec 15 15:10:16 UTC 2023`
Record UNII	V9MO595C9I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SALSALATE

Official Name

English

DISALCID

Brand Name

English

NSC-49171

Code

English

DISALICYCLIC ACID

Common Name

English

SASAPYRINE

Common Name

English

2-[(2-Hydroxybenzoyl)oxy]benzoic acid

Systematic Name

English

CARBASALATE CALCIUM IMPURITY D [EP IMPURITY]

Common Name

English

salsalate [INN]

Common Name

English

SALSALATE [MI]

Common Name

English

ACETYLSALICYLIC ACID IMPURITY E [EP IMPURITY]

Common Name

English

BENZOIC ACID, 2-HYDROXY-, 2-CARBOXYPHENYL ESTER

Common Name

English

SALSALATE [MART.]

Common Name

English

SALSALATE [USAN]

Common Name

English

SALICYLSALICYLIC ACID

Common Name

English

Salsalate [WHO-DD]

Common Name

English

DL-LYSINE ACETYLSALICYLATE IMPURITY M [EP IMPURITY]

Common Name

English

SALSALATE [USP IMPURITY]

Common Name

English

SALSALATE [USP-RS]

Common Name

English

SASAPYRINE [JAN]

Common Name

English

SALSALATE [VANDF]

Common Name

English

SALICYLIC ACID, BIMOLECULAR ESTER

Common Name

English

SALSALATE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N02BA06